Correction to “Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis?”

doi:10.1124/jpet.123.001661err

See original article:

Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis? - September 01, 2023

In the above article, [Andresen B (2023) Could a Nebulized or Dry Powder Inhalation of a Dopamine D1R Agonist Be a Treatment of Idiopathic Pulmonary Fibrosis? J Pharmacol Exp Ther, 386:274–276; DOI: https://doi.org/10.1124/jpet.123.001661], the reference to Gao et al. was accidentally omitted from the References section due to a compositor error. The full reference is provided below.

Gao AY, Diaz Espinosa AM, Nguyen BBN, Link PA, Meridew J, Jones DL, Gibbard DF, Tschumperlin DJ, and Haak AJ (2023) DRD1 is exempt from TGFβ-mediated antifibrotic GPCR landscape tampering in lung fibroblasts. J Pharmacol Exp Ther 386:277–287.

The HTML and PDF versions of the article have been corrected.

The compositor apologizes for any inconvenience this error has caused.